In early 2026, Moderna reported encouraging long-term data for its personalized cancer vaccine mRNA-4157 (V940) in high-risk ...

They aren't just "pandemic stocks." ...

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

The deal would provide ‘certainty’ for Moderna’s vaccine portfolio.

The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.

The U.S. Food and Drug Administration (FDA) recently informed Moderna that it would not review the company’s application for approval of its new flu vaccine, which is its first using mRNA technology ...

Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding charge expected in ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used ...

Moderna will pay US$950-million upfront in July, 2026, with an additional US$1.3-billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its ...

An early Moderna COVID‑19 trial has resurfaced six years on, amid ongoing debate over vaccine risks, guidance and public trust.